Fesoterodine

Generic Name: Fesoterodine

Brand Names: Toviaz

Drug Type: Small Molecule

Chemical Formula: C_₂₆H_₃₇NO_₃

CAS Number: 286930-02-7

Unique Ingredient Identifier: 621G617227

Background: Fesoterodine is an antimuscarinic prodrug for the treatment of overactive bladder syndrome.

Indication: 适用于治疗急迫性尿失禁和膀胱过度活动综合征患者的尿频、尿急、尿失禁或所有这些症状组合。

Associated Conditions: Neurogenic Detrusor Overactivity, Overactive Bladder Syndrome (OABS)

Clinical Trials

A Study To Estimate The Effects Of Food On Drug Fesoterodine Fumarate And The Pharmacokinetics Of 5-Hydroxymethyl Tolterodine (5-HMT) In Healthy Volunteers

Phase 1

Completed

Conditions: Urinary Bladder, Overactive

Interventions: Drug: fesoterodine fumarate

First Posted Date: 2012-03-29

Last Posted Date: 2016-08-19

Lead Sponsor: Pfizer

Target Recruit Count: 24

Registration Number: NCT01566760

Locations: 🇸🇬
Pfizer Investigational Site, Singapore, Singapore

A Study To Find Out How Fesoterodine Works In Children Aged 6 To 17 Years With Bladder Overactivity Caused By A Neurological Condition

Phase 3

Completed

Conditions: Urinary Bladder, Neurogenic

Interventions: Drug: Fesoterodine BIC 4 mg
Drug: Fesoterodine PR 4 mg
Drug: Fesoterodine PR 8 mg
Drug: Fesoterodine BIC 2 mg
Drug: Oxybutynin
Drug: Fesoterodine PR

First Posted Date: 2012-03-19

Last Posted Date: 2021-02-02

Lead Sponsor: Pfizer

Target Recruit Count: 181

Registration Number: NCT01557244

Locations: 🇧🇪
Hôpital Universitaire des Enfants Reine Fabiola, Bruxelles, Bruxelles-capitale, Belgium
🇯🇵
Kanagawa Children's Medical Center, Yokohama, Kanagawa, Japan
🇯🇵
Fukuoka Children's Hospital, Fukuoka-shi, Fukuoka, Japan

and more 80 locations

Comparative Urine Proteomic Studies of Overactive Bladder in Humans

Not Applicable

Completed

Conditions: Overactive Bladder

Interventions: Drug: fesoterodine

First Posted Date: 2011-06-07

Last Posted Date: 2015-02-27

Lead Sponsor: Washington University School of Medicine

Target Recruit Count: 21

Registration Number: NCT01367886

Locations: 🇺🇸
Washington University School of Medicine, St. Louis, Missouri, United States

A Clinical Study in Patients With Overactive Bladder With Leakage of Urine, to Find Out if the Medicine, Fesoterodine, Works in Those Patients Who Did Not Have Enough Response to the Medicine, Tolterodine.

Phase 4

Completed

Conditions: Urinary Bladder, Overactive

Interventions: Drug: Fesoterodine 8 mg
Drug: Placebo

First Posted Date: 2011-02-23

Last Posted Date: 2018-12-04

Lead Sponsor: Pfizer

Target Recruit Count: 990

Registration Number: NCT01302054

Locations: 🇺🇸
Women's Specialty Center, Jackson, Mississippi, United States
🇺🇸
CRC of Jackson, Jackson, Mississippi, United States
🇺🇸
Advances In Health, Inc., Houston, Texas, United States

and more 157 locations

A 12 Week Study to Confirm the Effectiveness of 8mg of Fesoterodine Compared to 4mg of Fesoterodine

Phase 4

Completed

Conditions: Overactive Bladder

Interventions: Drug: Placebo
Drug: Fesoterodine 8mg
Drug: Fesoterodine 4mg

First Posted Date: 2011-02-23

Last Posted Date: 2014-03-26

Lead Sponsor: Pfizer

Target Recruit Count: 2012

Registration Number: NCT01302067

Locations: 🇺🇸
Women's Healthcare Associates dba Rosemark WomenCare Specialists, Idaho Falls, Idaho, United States
🇺🇸
Institute for Female Pelvic Medicine, Allentown, Pennsylvania, United States
🇨🇦
Can-Med Clinical Research, Victoria, British Columbia, Canada

and more 274 locations

This Is A Study Of Bioavailability And Food Effect For Fesoterodine.

Phase 1

Completed

Conditions: Overactive Bladder (OAB) With Symptoms of Frequency, Urgency, and Urgency

Interventions: Drug: fesoterodine

First Posted Date: 2011-01-31

Last Posted Date: 2012-01-26

Lead Sponsor: Pfizer

Target Recruit Count: 20

Registration Number: NCT01286454

Locations: 🇺🇸
Pfizer Investigational Site, New Haven, Connecticut, United States

Post Marketing Surveillance Of Fesoterodine In Filipino Patients With Over Active Bladder

Completed

Conditions: Over Active Bladder

Interventions: Drug: Fesoterodine

First Posted Date: 2010-12-15

Last Posted Date: 2014-09-11

Lead Sponsor: Pfizer

Target Recruit Count: 508

Registration Number: NCT01260311

Locations: 🇵🇭
Mary Johnston Hospital, Inc., Tondo, Manila, Philippines
🇵🇭
The Medical City, Pasig City, Metro Manila, Philippines
🇵🇭
St. Luke's Medical Center, Quezon City, Metro Manila, Philippines

and more 21 locations

A Study to Assess the Cognitive Effects of Fesoterodine in Elderly Subjects

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: alprazolam 1mg
Drug: Placebo
Drug: 4mg fesoterodine
Drug: 8mg fesoterodine

First Posted Date: 2010-07-13

Last Posted Date: 2012-06-28

Lead Sponsor: Pfizer

Target Recruit Count: 20

Registration Number: NCT01161472

Locations: 🇺🇸
Pfizer Investigational Site, Overland Park, Kansas, United States

Local, Open-Label, Extension Trial Of The Efficacy And Safety Of Fesoterodine In Elderly Patients With Overactive Bladder

Phase 4

Completed

Conditions: Urinary Bladder, Overactive

Interventions: Drug: Fesoterodine

First Posted Date: 2010-01-22

Last Posted Date: 2013-05-15

Lead Sponsor: Pfizer

Target Recruit Count: 31

Registration Number: NCT01054222

Locations: 🇵🇹
Hospital Ordem do Carmo, Porto, Portugal
🇵🇹
Hospital de São João, Porto, Portugal
🇵🇹
Centro de Avaliação Geriátrica, Lisboa, Portugal

Evaluation Of The Ability Of Fesoterodine To Increase Urethral Pressure In Stress Urinary Incontinence Patients

Phase 2

Completed

Conditions: Stress Urinary Incontinence

Interventions: Drug: Fesoterodine

First Posted Date: 2010-01-05

Last Posted Date: 2011-07-22

Lead Sponsor: Pfizer

Target Recruit Count: 22

Registration Number: NCT01042236

Locations: 🇩🇰
Glostrup Hospital, Glostrup, Denmark

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy